Literature DB >> 30316026

Transferrin/aptamer conjugated mesoporous ruthenium nanosystem for redox-controlled and targeted chemo-photodynamic therapy of glioma.

Xufeng Zhu1, Hui Zhou1, Yanan Liu1, Yayu Wen1, Chunfang Wei1, Qianqian Yu1, Jie Liu2.   

Abstract

The blood-brain barrier (BBB) and low targeting are major obstacles for the treatment of gliomas. Accordingly, overcoming the BBB and enhancing the targeting of drugs to the glioma area are key to achieving a good therapeutic effect. Here, we have developed the mesoporous ruthenium nanosystem RBT@MRN-SS-Tf/Apt with dual targeting function. Transferrin (Tf) and aptamer AS1411 (Apt) are grafted on the surfaces of mesoporous ruthenium nanoparticles (MRN) with high loading capacity. This is achieved via redox-cleavable disulfide bonds, serving as both a capping agent and a targeting ligand, enabling the effective penetration of the blood-brain barrier and targeting the glioma. In addition, RBT@MRN-SS-Tf/Apt can specifically kill glioma cells in vitro and in vivo. Moreover, anti-tumor drugs [Ru(bpy)2(tip)]2+ (RBT) will produce reactive oxygen species and induce apoptosis of tumor cells under laser irradiation, providing photodynamic therapy (PDT) for the treatment of gliomas, and further prolonging the median survival period. The study shows that this chemical photodynamic therapy nanosystem can be used as an efficient and powerful synergistic system for the treatment of brain tumors and other brain diseases of the central nervous system. STATEMENT OF SIGNIFICANCE: In order to overcome the blood-brain barrier and low targeting, and enhance the anti-glioma activities of nanodrugs. We have developed RBT@MRN-SS-Tf/Apt with dual targeting function. It is achieved release drug via redox-cleavable disulfide bonds, and enable the effective penetration of the blood-brain barrier and targeting the glioma. Moreover, anti-tumor drugs RBT will produce reactive oxygen species and induce apoptosis of tumor cells under laser irradiation, providing photodynamic therapy (PDT) for the treatment of gliomas, and further prolonging the median survival period. Therefore, this chemical photodynamic therapy nanosystem can be used as an efficient and powerful synergistic system for the treatment of brain tumors and other brain diseases of the central nervous system.
Copyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AS1411; Dual targeting; Glioma; PDT; Redox; Response; Tf

Mesh:

Substances:

Year:  2018        PMID: 30316026     DOI: 10.1016/j.actbio.2018.10.012

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  14 in total

Review 1.  Critical discussion of the applications of metal complexes for 2-photon photodynamic therapy.

Authors:  Johannes Karges; Hui Chao; Gilles Gasser
Journal:  J Biol Inorg Chem       Date:  2020-11-04       Impact factor: 3.358

Review 2.  Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.

Authors:  Wiam El Kheir; Bernard Marcos; Nick Virgilio; Benoit Paquette; Nathalie Faucheux; Marc-Antoine Lauzon
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

3.  Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo.

Authors:  Sushant Lakkadwala; Bruna Dos Santos Rodrigues; Chengwen Sun; Jagdish Singh
Journal:  Nanomedicine       Date:  2019-10-25       Impact factor: 5.307

4.  Enhanced Anti-Glioma Efficacy by Borneol Combined With CGKRK-Modified Paclitaxel Self-Assembled Redox-Sensitive Nanoparticles.

Authors:  Lingyan Lv; Xinrui Li; Wei Qian; Shennan Li; Yan Jiang; Yaokun Xiong; Jianpei Xu; Wei Lv; Xiaoyan Liu; Yun Chen; Yulin Tang; Hongliang Xin
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 5.  Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review.

Authors:  Jie Li; Jiaqian Zhao; Tiantian Tan; Mengmeng Liu; Zhaowu Zeng; Yiying Zeng; Lele Zhang; Chaomei Fu; Dajing Chen; Tian Xie
Journal:  Int J Nanomedicine       Date:  2020-04-17

6.  Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma.

Authors:  Yuanhao Chang; Guanzhang Li; You Zhai; Lijie Huang; Yuemei Feng; Di Wang; Wei Zhang; Huimin Hu
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 7.  Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.

Authors:  Piotr Gierlich; Ana I Mata; Claire Donohoe; Rui M M Brito; Mathias O Senge; Lígia C Gomes-da-Silva
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

Review 8.  Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.

Authors:  Valeriana Cesarini; Chiara Scopa; Domenico Alessandro Silvestris; Andrea Scafidi; Valerio Petrera; Giada Del Baldo; Angela Gallo
Journal:  Molecules       Date:  2020-09-17       Impact factor: 4.411

9.  Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy.

Authors:  Minmin Chen; Jinxia Hu; Lujing Wang; Yanru Li; Chenghao Zhu; Chen Chen; Ming Shi; Zhicheng Ju; Xichuan Cao; Zhuoqi Zhang
Journal:  Sci Rep       Date:  2020-09-02       Impact factor: 4.379

Review 10.  Aptamer Applications in Neuroscience.

Authors:  Meric Ozturk; Marit Nilsen-Hamilton; Muslum Ilgu
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.